Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection

Area of Science:

• Thoracic Surgery
• Surgical Oncology
• Pulmonary Medicine

Background:

• The Commission on Cancer updated lung cancer resection standards, recommending sampling 3 mediastinal (N2) and 1 hilar (N1) lymph node stations.
• The impact of this guideline-concordant lymph node sampling on patient outcomes remains under investigation.

Purpose of the Study:

• To evaluate the association between guideline-concordant lymph node sampling (3 N2, 1 N1) and oncologic outcomes in lung cancer resections.
• To assess the relationship between guideline concordance and nodal upstaging, complications, adjuvant therapy, recurrence, and survival.

Main Methods:

• A prospective institutional database was queried for clinical stage I-III lung resections performed prior to guideline implementation.
• Multivariable models were used to analyze outcomes, stratified by clinical stage, comparing guideline-concordant (3 N2, 1 N1) to nonconcordant sampling.

Main Results:

• Of 9289 resections, 33% were guideline concordant. Concordant sampling was associated with higher rates of nodal upstaging (21% vs 13%) and in-hospital complications (34% vs 27%).
• Adjuvant systemic therapy administration was similar between groups. No significant improvement in locoregional or distant recurrence was observed across stages.
• Overall survival was similar for clinical stages I and II, but significantly improved for guideline-concordant clinical stage III patients (HR, 0.85).

Conclusions:

• Guideline-concordant lymph node sampling (3 N2, 1 N1) increases nodal upstaging and complications but does not reduce recurrence or mortality in clinical stages I and II lung cancer.
• Improved survival was observed in guideline-concordant clinical stage III patients, suggesting a potential benefit in advanced disease.
• Further research is warranted to determine the optimal lymph node sampling strategy for diverse lung cancer patient populations.